Association of HLA Class II Alleles with Disease Severity and Treatment Response in Iranian Patients with Myasthenia Gravis

被引：1

作者：

Sinaei, Farnaz ^{[1
]}

Fatehi, Farzad ^{[1
]}

Gharan, Shahram Oveis ^{[1
,2
]}

Ehsan, Soroush ^{[1
]}

Kamali, Koorosh ^{[3
]}

Amirzargar, Aliakbar ^{[4
,5
]}

Mahmoudi, Mahdi ^{[6
]}

Vaghefifar, Alaleh ^{[1
]}

Nafissi, Shahriar ^{[1
]}

机构：

[1] Univ Tehran Med Sci, Shariati Hosp, Dept Neurol, Tehran, Iran

[2] Rush Univ, Med Ctr, Rush Alzheimer Dis Ctr, Chicago, IL 60612 USA

[3] Zanjan Univ Med Sci, Sch Publ Hlth, Dept Publ Hlth, Zanjan, Iran

[4] Univ Tehran Med Sci, Mol Immunol Res Ctr, Sch Med, Tehran, Iran

[5] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran

[6] Univ Tehran Med Sci, Shariati Hosp, Rheumatol Res Ctr RRC, Tehran, Iran

来源：

JOURNAL OF NEUROMUSCULAR DISEASES | 2021年 / 8卷 / 05期

关键词：

Myasthenia gravis; treatment; severity; HLA class II;

D O I：

10.3233/JND-210700

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Myasthenia gravis is an autoimmune neuromuscular disease with a multifactorial etiology. A major part of the genetic susceptibility belongs to theHLAencoding genes. In this study, we investigated the role ofHLAclass II polymorphism in disease severity, and treatment response. In our 146 patients, 15 DRB1, 7DQA1, and 9DQB1 alleles, and 19 haplotypes were found. Adjusted p-values did not show any significant associations between these loci, disease severity and treatment outcome. Further studies in different populations with a larger number of patients are needed to determine the exact contribution of HLA class II alleles to MG prognosis.

引用

页码：827 / 829

页数：3

共 50 条

[1] HLA class II polymorphism contribution to disease severity and response to treatment in myasthenia gravis
Sinaei, F.
Nafissi, S.
Fatehi, F.
Gharan, S. Oveis
Ehsan, S.
Kamali, K.
Mahmoudi, M.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
[2] Disease severity and response to treatment in Iranian patients with myasthenia gravis
Farnaz Sinaei
Farzad Fatehi
Shahram Oveis Gharan
Soroush Ehsan
Koorosh Kamali
Shahriar Nafissi
Neurological Sciences, 2022, 43 : 1233 - 1237
[3] Disease severity and response to treatment in Iranian patients with myasthenia gravis
Sinaei, Farnaz
Fatehi, Farzad
Gharan, Shahram Oveis
Ehsan, Soroush
Kamali, Koorosh
Nafissi, Shahriar
NEUROLOGICAL SCIENCES, 2022, 43 (02) : 1233 - 1237
[4] DISTINCT TYPES OF MYASTHENIA GRAVIS DIFFER BY ASSOCIATION WITH HLA CLASS II ALLELES
Testi, Manuela
Greco, Giulia
Troiano, Maria
Rastelli, Emanuele
Pompeo, Eugenio
Antonini, Giovanni
Andreani, Marco
Massa, Roberto
HLA, 2018, 91 (05) : 465 - 465
[5] No association of the HLA-DQ alleles with myasthenia gravis in Cuban patients
Sylvia, Torres
Samuel, Morales
Luis, Gonzales
Zuzet, Martinez
HUMAN IMMUNOLOGY, 2013, 74 (08) : 983 - 985
[6] HLA class I and class II polymorphisms in Saudi patients with myasthenia gravis
Hajeer, A. H.
Al Sawidan, F.
Bohlega, S.
Saleh, S.
Sutton, P.
Shubaili, A.
Al Tahan, A.
Al Jumah, M.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2009, 36 (03) : 169 - 172
[7] HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis
Fernández-Mestre, MT
Vargas, V
Montagnani, S
Cotúa, M
Ogando, V
Layrisse, Z
HUMAN IMMUNOLOGY, 2004, 65 (01) : 54 - 59
[8] HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis
García-Ramos, G
Téllez-Zenteno, JF
Zapata-Zúñiga, M
Yamamoto-Furusho, JK
Ruiz-Morales, JA
Villarreal-Garza, C
Vargas-Alarcón, G
Estañol, B
Llorente, L
Granados, J
EUROPEAN JOURNAL OF NEUROLOGY, 2003, 10 (06) : 707 - 710
[9] Association of HLA class II (DRB1, DQA1, DQB1) alleles and haplotypes with myasthenia gravis and its subgroups in the Iranian population
Ehsan, Soroush
Amirzargar, Aliakbar
Yekaninejad, Mir Saeed
Mahmoudi, Mahdi
Mehravar, Saeed
Moradi, Batoul
Nafissi, Shahriar
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 359 (1-2) : 335 - 342
[10] Association between HLA class II alleles and severity of liver disease in chronic HCV infection
Martinelli, ALC
Louzada-Junior, P
Rodripues, SS
Villanova, MG
Figueiredo, JFC
Passos, ADC
Secaf, M
Covas, DT
Zucoloto, S
Donadi, EA
HEPATOLOGY, 1998, 28 (04) : 683A - 683A

← 1 2 3 4 5 →